Logo

NIH Pledges $3M for Pharmacogenomics Studies of Mood and Anxiety Disorders

Sep 05, 2003

NEW YORK, Sept. 5 (GenomeWeb News) - The National Institutes of Health announced today that it will commit $3 million in financial year 2004 to fund the use of genomic methods to track responses to drugs used to treat mood or anxiety disorders.

 

"The underlying theme of this RFA will be to search across the genome for pharmacogenetically important sequence variations by correlating genotype with treatment response," the Request for Applications stated. A particular focus, according to the NIH, will be the construction of haplotypes for pharmacogenetic prediction.

 

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.